



Reference Guide: Supporting Evidence for “Rh-Negative Pregnancy” Educational Resources

Provided by the Allo Hope Foundation, July 2026

View patient and provider resources at:

<https://allohopefoundation.org/rh-immune-globulin/>

Professional Society Recommendations

American College of Obstetricians and Gynecologists (ACOG): Pregnancy Loss <12 Weeks
ACOG Clinical Practice Update. Rh D Immune Globulin Administration After Abortion or Pregnancy Loss at Less Than 12 Weeks of Gestation. Obstet Gynecol. 2024;144(6):e140-e143.

Society for Maternal-Fetal Medicine (SMFM)- Pregnancy Loss <12 Weeks

Prabhu M, Louis JM, Kuller JA; Society for Maternal-Fetal Medicine; SMFM Publications Committee. Society for Maternal-Fetal Medicine Statement: RhD immune globulin after spontaneous or induced abortion at less than 12 weeks of gestation. Am J Obstet Gynecol. 2024;230(5):B2-B5.

Society for Maternal-Fetal Medicine (SMFM): Fetal RhD Genotyping

Rink BD, Kuller JA, Sparks TN, Prabhu M, Mardy AH, Dugoff L, Biggio JR, SMFM Publications Committee. Society for Maternal-Fetal Medicine Statement: Evaluation and management of cell-free DNA screening for fetal red cell antigen genotype in alloimmunized and non-alloimmunized pregnancies. Pregnancy. 2026;2:e70339.

RhIg Clinical Effectiveness

Risk of alloimmunization without prophylaxis: 16%

Bowman JM. *The prevention of Rh immunization*. Transfus Med Rev. 1988;2(3):129-150.

Risk Reduction to 0.1%

Yoham AL, Casadesus D. *Rho(D) Immune Globulin*. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; Updated May 22, 2023.

RhoGAM Half Life:

RhoGAM® Ultra-Filtered PLUS. Half-Life of RhoGAM. Available at:

<https://hcp.rhogam.com/why-rhogam/half-life/>

Clinical pharmacokinetics: undetectable within six months

Stucki M, Schnorf J, Hustinx H, Gerber H, Lerch PG, Halabi A, Kleinbloesem CH, Morell A. *Anti-D immunoglobulin in Rh(D)-negative volunteers: clearance of Rh(D)-positive red cells and kinetics of serum anti-D levels*. Transfuse Clin Biol. 1998;5(3):180-188.

HDFN Risks and Treatments

Approximately 36% of fetuses are Rh negative

Schimanski B, Kräuchi R, Stettler J, Lejon Crottet S, Niederhauser C, Clausen FB, Fontana S, Hodel M, Amylidi-Mohr S, Raio L, et al. *Fetal RHD Screening in RH1 Negative Pregnant Women: Experience in Switzerland*. Biomedicines. 2023;11(10):2646.

Approximately 38% of fetuses are Rh negative

Finning K, Martin P, Summers J, Massey E, Poole G, Daniels G. *Effect of high throughput RHD typing of fetal DNA in maternal plasma on use of anti-RhD immunoglobulin in RhD negative pregnant women: prospective feasibility study*. BMJ. 2008;336(7648):816-818. doi:10.1136/bmj.39518.463206.25.

Approximately 13% of alloimmunized pregnancies require intrauterine transfusion for HDFN, mortality up to 20%

de Winter DP, Kaminski A, Tjoa ML, Oepkes D. *Hemolytic disease of the fetus and newborn: systematic literature review of the antenatal landscape*. BMC Pregnancy Childbirth. 2023;23(1):12.